PetMed Express, Inc. filed an 8-K current report on September 21, 2026, disclosing the appointment of Tamar Elkeles, Ph.D., to its Board of Directors, effective September 17, 2026.
Key Highlights
- New Director: Tamar Elkeles, Ph.D., was appointed to the PetMed Express Board of Directors, effective September 17, 2026.
- Board Size Increased: In connection with the appointment, the Board increased its membership from 4 to 5 directors.
- Committee Assignments: Dr. Elkeles was appointed immediately to the Compensation and Human Capital Committee and the Corporate Governance and Nominating Committee.
- Independent Director: The Board determined that Dr. Elkeles qualifies as an independent director under Nasdaq Stock Market listing standards and the Company's Corporate Governance Guidelines.
- Term: Dr. Elkeles will serve until the 2027 annual meeting of shareholders, or until her successor is elected and qualified, subject to earlier resignation or removal.
- Experience: Dr. Elkeles, age 57, has over 30 years of experience as an executive, board member, and strategic advisor in technology, enterprise software, and human capital industries.
PetMed Express Board Expands with Appointment of Dr. Tamar Elkeles
According to the filing, PetMed Express, Inc. (NASDAQ:PETS) disclosed that its Board of Directors appointed Tamar Elkeles, Ph.D., as a director on September 15, 2026, with the appointment taking effect on September 17, 2026. The Board simultaneously increased its size to 5 members. Dr. Elkeles will serve through the Company's 2027 annual shareholder meeting, subject to earlier resignation or removal.
The filing describes Dr. Elkeles as having served as Chief Human Resources Officer of XCOM Labs (now known as Virewirx) from January 2019 to June 2022. Since December 2022, she has served as a Senior Advisor at East Wind Advisors, an independent, industry-focused investment bank. She currently serves on the board of directors of Brightline Interactive (NASDAQ: BTLN), where she chairs the Compensation Committee and the Nominating and Governance Committee. She previously served on the boards of G3 VRM Acquisition Corp. (NASDAQ: GGGV) and GP Strategies Corporation. Dr. Elkeles holds an M.S. and Ph.D. in Organizational Psychology from the California School of Professional Psychology and a B.A. in psychology and human development from the University of Kansas.
The filing states that Dr. Elkeles will receive compensation under the Company's Non-Employee Director Compensation Program, filed as Exhibit 10.7 to the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2026. The Company also disclosed its intention to enter into an indemnification agreement with Dr. Elkeles in the same form used for its other directors. The filing confirms there are no family relationships between Dr. Elkeles and any director or executive officer, and no arrangements with other persons regarding her selection.
What Was Disclosed
PetMed Express reported the appointment of Tamar Elkeles, Ph.D., as an independent director effective September 17, 2026, the expansion of the Board to 5 members, her committee assignments, and the compensation and indemnification arrangements applicable to her service.




Please wait processing your request...